Sparta is creating the first-of-its-kind synthetic cartilage platform, Galene.
The degeneration of cartilage between the joints can cause significant personal, economic, societal burden for individuals, families, and communities. In addition, acute injuries to joint cartilage can exacerbate and become debilitating over time.
We are developing cartilage-like implants so one’s life is no longer burdened by pain and immobility.
We are a team of operators, technologists, scientists, and engineers with long histories in the pharma, medtech, and nuclear arenas.
We all have friends and family who are suffering from knee pain and limited range of motion. This is not only a problem locally, but globally. Over 500M suffer from osteoarthritis (OA). There are 16M visits in the US specifically for knee symptoms. In addition, there are hundreds of thousands osteochondral repairs per year. Unfortunately, there is a high percentage of patients who have a revision within two years. In addition, there are several million people getting a total knee replacement each year. A third of them were considered inappropriate candidates for this intervention. This issue also afflicts active military. Limited duty days exceed 1M after chondral procedures. One in three veterans have OA. The overall prevalence of knee cartilage lesions in high performance athletes is almost 40%.
We understand that behaviors and the environment can affect how one’s genes work. Furthermore, chronological age refers to the actual amount of time a person has existed, while biological age refers to epigenetic alteration and DNA methylation which express on how able and functioning a person is. The biological age of a joint is no different. Its condition is a result of prior injury, person’s daily routine, profession and diet.
Our proprietary Galene platform was developed with this reality in mind. This platform renders biological age inconsequential. Unlike cartilage regeneration technologies which take many months, if not years, to regrow strong cartilage, Galene mimics the properties of hyaline cartilage at time zero. This platform was developed at the intersection of materials science, chemistry, and engineering. Through a novel process of combining unique materials and well-known polymers, we created a bionic cartilage which replicates the tensile, compression, and wear properties in the joints of the shoulder, great toe, thumb, elbow, spine, and talus. We modified the geometry and configuration based on the anatomical location of interest. This allows us to more precisely and effectively address the needs of patients afflicted with osteoarthritis and cartilage defects. Our approach has the potential to provide patients with immediate pain reduction, full range of motion, resulting in a quality of life they desire.
The Ormi Circular Femoral Condyle (Ormi-CFC) implant, a Breakthrough Device, was created by combining Galene with an osseointegrative titanium base. Ormi-CFC is intended to treat chondral and osteochondral lesions of the femoral condyle.
A Target Product Profile (TPP) is a set of outcomes that focuses our efforts on building a solution that meaningfully improves that standard of care. Along with satisfying many safety requirements, we set a high bar on those outcomes that matter most for patients. Our TPP is unmatched by existing treatments and technologies in development. We believe this will instill confidence in surgeons as they help their patients quickly resume their daily routines and while knowing many productive years lay ahead.
Surgeons can take comfort in knowing their patients will quickly resume their routines and have highly productive lives many years to come.
We are building a substantial pipeline of Ormí solutions. We will leverage all the know-how and preclinical testing from our knee indication and create efficient and cost effective development paths for these additional indications.